First line HIV treatment involves antiretroviral therapy (ART), which helps control the human immunodeficiency virus and supports long term health. Treatment commonly combines multiple antiretroviral medicines to suppress viral replication and reduce the amount of HIV in the blood. Integrase strand transfer inhibitor based regimens are frequently recommended for people beginning treatment.
First line HIV treatment refers to the initial antiretroviral medication regimen prescribed to a person who has been diagnosed with HIV and is beginning therapy. The main objective is to achieve and maintain viral suppression, preserve immune function, and prevent disease progression.
Many recommended initial regimens contain an integrase strand transfer inhibitor (INSTI) combined with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). These medicines work at different stages of the HIV life cycle, limiting the virus's ability to reproduce.
Common first line treatment options include:
Bictegravir with tenofovir alafenamide and emtricitabine: This combination is available as a single-tablet regimen for many people beginning HIV treatment.
Dolutegravir with tenofovir and lamivudine: This combination is commonly used where appropriate, depending on clinical findings and national guidelines.
Dolutegravir with tenofovir alafenamide or tenofovir disoproxil fumarate and emtricitabine or lamivudine: These combinations provide alternative options based on individual requirements and medicine availability.
Alternative regimens: Other combinations may be considered when drug resistance, existing medical conditions, pregnancy-related considerations, or medication interactions affect the choice of treatment.
Before selecting a regimen, healthcare professionals may evaluate viral load, CD4 cell count, kidney and liver function, hepatitis B status, and potential drug resistance. Not every combination is suitable for every person, so treatment decisions require individualized clinical assessment.
HIV medications are combined to improve viral suppression and reduce the likelihood of treatment failure. Different medicines target specific viral processes, making it more difficult for HIV to multiply when treatment is taken consistently. The exact combination depends on the person's medical history, laboratory findings, and other medicines they use.
Important considerations during treatment include:
Medication adherence: Taking prescribed medicines consistently helps maintain viral suppression and reduces the risk of developing drug resistance.
Viral load testing: Blood tests measure the amount of HIV in the blood and help determine whether treatment is working effectively.
CD4 cell monitoring: CD4 measurements help assess immune system health and recovery over time.
Side effect assessment: Some medicines may cause nausea, headache, sleep disturbances, or other effects. Persistent or severe symptoms should be discussed with a healthcare professional.
Drug interactions: Prescription medicines, over-the-counter products, supplements, and certain antacids can affect how some HIV medications work.
Regular clinical reviews: Follow-up appointments help healthcare professionals evaluate treatment effectiveness and decide whether adjustments are necessary.
People with HIV who maintain an undetectable viral load through effective treatment do not sexually transmit HIV. This principle is known as Undetectable Equals Untransmittable, or U=U.
First line HIV treatments are an important part of comprehensive HIV care. With an appropriate medication combination, regular monitoring, and consistent adherence, many people living with HIV can achieve sustained viral suppression and maintain their overall health. Treatment should always be initiated and adjusted under the guidance of a qualified healthcare professional using current clinical guidelines.